Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for Canada

Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application (BLA) route based on the recommendation of the US drug regulator.